Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment

Jessica Madera,1 Pedro Such,2 Peter Zhang,1 Ross A Baker,1 Iria Grande31Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, NJ, USA; 2Medical Affairs, H. Lundbeck A/S, Valby, Denmark; 3Bipolar and Depression Disorders Unit, Hospital Clinic, Institute of Neuroscie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Madera J, Such P, Zhang P, Baker RA, Grande I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Bipolar disorder aripiprazole long-acting injectable maintenance functioning recovery Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6250f530d85c46ba80cb813e2ce4bb79
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6250f530d85c46ba80cb813e2ce4bb79
record_format	dspace
spelling	oai:doaj.org-article:6250f530d85c46ba80cb813e2ce4bb792021-12-02T10:48:27ZUse of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment1178-2021https://doaj.org/article/6250f530d85c46ba80cb813e2ce4bb792019-08-01T00:00:00Zhttps://www.dovepress.com/use-of-the-functioning-assessment-short-test-fast-in-defining-function-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jessica Madera,1 Pedro Such,2 Peter Zhang,1 Ross A Baker,1 Iria Grande31Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, NJ, USA; 2Medical Affairs, H. Lundbeck A/S, Valby, Denmark; 3Bipolar and Depression Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, SpainPurpose: There is growing agreement that definitions of “recovery” in bipolar-I disorder (BP-I) should include functional outcomes beyond sustained symptomatic remission. In this post-hoc analysis, we assessed functional recovery rates according to the validated Functioning Assessment Short Test (FAST) in participants with BP-I after 52 weeks of maintenance treatment with aripiprazole once monthly (AOM).Patients and methods: Rates of functional recovery with AOM 400 were investigated in two 52-week studies. NCT01567527 was a placebo-controlled, double-blind, randomized-withdrawal study and NCT01710709 was an open-label study. Functional recovery, assessed at the end of the respective maintenance phases, was defined as a total FAST score of ≤11 for 8 consecutive weeks.Results: Post-hoc analyses included 229 patients from the randomized-withdrawal study (AOM 400 n=116; placebo n=113). The open-label study included 402 patients (including 321 de novo patients and 81 rollover patients who had completed the randomized-withdrawal study). In the randomized-withdrawal study, functional recovery was achieved by 30.2% (n=35) of the AOM 400 group compared with 24.8% (n=28) in the placebo group. The difference was not statistically significant (p=0.39). In the open-label study, 36% (n=116) of de novo patients and 43% (n=35) of rollover patients had functionally recovered after 52 weeks of AOM 400 treatment.Conclusion: These data highlight the utility of a sustained FAST total score of ≤11 as a definition of recovery and emphasize the possibility of achieving this ambitious treatment goal with effective long-term treatment.Keywords: bipolar disorder, aripiprazole, long-acting injectable, maintenance, functioning, recoveryMadera JSuch PZhang PBaker RAGrande IDove Medical PressarticleBipolar disorderaripiprazolelong-acting injectablemaintenancefunctioningrecoveryNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2325-2338 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bipolar disorder aripiprazole long-acting injectable maintenance functioning recovery Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Bipolar disorder aripiprazole long-acting injectable maintenance functioning recovery Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Madera J Such P Zhang P Baker RA Grande I Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
description	Jessica Madera,1 Pedro Such,2 Peter Zhang,1 Ross A Baker,1 Iria Grande31Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, NJ, USA; 2Medical Affairs, H. Lundbeck A/S, Valby, Denmark; 3Bipolar and Depression Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, SpainPurpose: There is growing agreement that definitions of “recovery” in bipolar-I disorder (BP-I) should include functional outcomes beyond sustained symptomatic remission. In this post-hoc analysis, we assessed functional recovery rates according to the validated Functioning Assessment Short Test (FAST) in participants with BP-I after 52 weeks of maintenance treatment with aripiprazole once monthly (AOM).Patients and methods: Rates of functional recovery with AOM 400 were investigated in two 52-week studies. NCT01567527 was a placebo-controlled, double-blind, randomized-withdrawal study and NCT01710709 was an open-label study. Functional recovery, assessed at the end of the respective maintenance phases, was defined as a total FAST score of ≤11 for 8 consecutive weeks.Results: Post-hoc analyses included 229 patients from the randomized-withdrawal study (AOM 400 n=116; placebo n=113). The open-label study included 402 patients (including 321 de novo patients and 81 rollover patients who had completed the randomized-withdrawal study). In the randomized-withdrawal study, functional recovery was achieved by 30.2% (n=35) of the AOM 400 group compared with 24.8% (n=28) in the placebo group. The difference was not statistically significant (p=0.39). In the open-label study, 36% (n=116) of de novo patients and 43% (n=35) of rollover patients had functionally recovered after 52 weeks of AOM 400 treatment.Conclusion: These data highlight the utility of a sustained FAST total score of ≤11 as a definition of recovery and emphasize the possibility of achieving this ambitious treatment goal with effective long-term treatment.Keywords: bipolar disorder, aripiprazole, long-acting injectable, maintenance, functioning, recovery
format	article
author	Madera J Such P Zhang P Baker RA Grande I
author_facet	Madera J Such P Zhang P Baker RA Grande I
author_sort	Madera J
title	Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
title_short	Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
title_full	Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
title_fullStr	Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
title_full_unstemmed	Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
title_sort	use of the functioning assessment short test (fast) in defining functional recovery in bipolar i disorder. post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/6250f530d85c46ba80cb813e2ce4bb79
work_keys_str_mv	AT maderaj useofthefunctioningassessmentshorttestfastindefiningfunctionalrecoveryinbipolaridisorderposthocanalysesoflongtermstudiesofaripiprazoleoncemonthlyasmaintenancetreatment AT suchp useofthefunctioningassessmentshorttestfastindefiningfunctionalrecoveryinbipolaridisorderposthocanalysesoflongtermstudiesofaripiprazoleoncemonthlyasmaintenancetreatment AT zhangp useofthefunctioningassessmentshorttestfastindefiningfunctionalrecoveryinbipolaridisorderposthocanalysesoflongtermstudiesofaripiprazoleoncemonthlyasmaintenancetreatment AT bakerra useofthefunctioningassessmentshorttestfastindefiningfunctionalrecoveryinbipolaridisorderposthocanalysesoflongtermstudiesofaripiprazoleoncemonthlyasmaintenancetreatment AT grandei useofthefunctioningassessmentshorttestfastindefiningfunctionalrecoveryinbipolaridisorderposthocanalysesoflongtermstudiesofaripiprazoleoncemonthlyasmaintenancetreatment
_version_	1718396650219634688

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment

Ejemplares similares